摘要
目的评价分析30例急性心肌梗死患者采用重组人尿激酶原溶栓治疗的疗效及安全性。方法随机选取我院2011年6月至2013年6月间的急性心肌梗死患者60例,根据治疗方法的不同分为试验组(30例)和对照组(30例)。给予试验组患者重组人尿激酶原溶栓治疗,给予对照组患者常规肝素治疗。记录患者TIMI分级结果和随访过程中的心脏事件发生情况,以比较两组不同治疗方法的临床疗效及安全性。结果溶栓治疗后,试验组的完全再通率(76.67%)优于对照组(46.67%),试验组的再通率(86.67%)优于对照组(63.33%),差异均具有统计学意义(P<0.05)。两组患者的死亡例数均为0。试验组的再次心肌梗死率(0.00%)低于对照组(3.33%),试验组患者的心力衰竭率(3.33%)低于对照组(10.00%),两组差异均无统计学意义(P>0.05)。试验组患者的梗死后心绞痛发病率(16.67%)低于对照组(43.33%),试验组患者的出血率(3.33%)低于对照组(26.67%),两组差异均具有统计学意义(P<0.05)。结论采用重组人尿激酶原溶栓治疗急性心肌梗死患者具有疗效可靠和安全性高的显著优势,值得临床的广泛应用和推广。
Objective To evaluate the efficacy and safety of thrombolytic therapy with recombinant human prourokinase for patients with acute myocardial infarction. Methods 60 patients with acute myocardial infarction in our hospital from June 2011 to June 2013 were selected and divided into test group （30 cases） and control group （30 cases） according to the therapeutic methods. The test group received thrombolytic therapy with recombinant human prourokinase, while the control group received regular heparin therapy. The TIMI grade results and the occurrences of cardiac events during follow-up process were recorded to evaluate the clinical effect and safety of two methods. Results After treatment, the complete recanalization rate and recanalization rate of test group were 76.67% and 86.67% respectively, significantly higher than 46.67% and 63.33% of control group correspondingly （both P〈0.05）. No death case was found in both groups. The incidence of second myocardial infarction and the incidence of heart failure of test group were lower than those of control group （0.00% vs. 3.33%, 3.33% vs. 10.00%, respectively）, but the differences between two groups were not statistically significant （P〉0.05）. The incidence of angina pectoris after infarction and bleeding rate of test group were lower than those of control group （16.67% vs. 43.33%, 3.33% vs. 26.67%, respectively）, and the difference was statistically significant （P 〈0.05）. Conclusions Thrombolytic therapy with recombinant human prourokinase for patients with acute myocardial infarction has advantages of reliable curative effect and high safety, which is worthy of clinical application and promotion.
出处
《临床医学工程》
2014年第4期469-470,共2页
Clinical Medicine & Engineering
关键词
急性心肌梗死
重组人尿激酶原溶栓
疗效
安全性
Acute myocardial infarction
Thrombolytic therapy with recombinant human prourokinase
Efficacy
Safety
